Novartis

Novartis

Novartis is a healthcare and pharmaceutical company based in Basel, Switzerland, incorporated in 1996.

Novartis products include oncology medicines, generic and biosimilar medicines and eye car devices. The Innovative Medicine segment of the company is divided into Novartis Oncology and Novartis Pharmaceuticals. Novartis Pharmaceuticals consists of global business franchises in ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic and established medicines.

Sandoz is a division of Novartis that manufactures, distributes and sells prescription medicines and pharmaceutical active substances that are not patent protected and is franchised into Retail generics, Anti-Infectives and Biopharmaceuticals.

Alcon is a division of Novartis in the eye car product field in eye care devices and vision care. Alcon’s surgical franchise includes technologies and devices for cataract, retinal, glaucoma and refractive surgery and intraocular lenses to treat cataracts and refractive errors. Alcon’s Vision Care franchise includes contact lenses and contact lens care products. Alcon’s surgical portfolio also includes equipment for performing cataract surgery.

Novartis, previously called Ciba-Geigy, was one of the few pharmaceutical companies involved in tyrosine kinase inhibitor research when it began a collaboration with oncologist Brian Druker which resulted in discovery of the kinase inhibitor drug Gleevec (also known as Glivec or imatinib). Gleevec was FDA approved in 2001 to treat patients with chronic myelogenous leukemia (CML). Kinases perform phosphorylation, a mechanism that controls the activity of proteins in the cell. CML patients have a mutation causing their tyrosine kinase to be overactive, which signals cell to proliferate at a high rate, resulting in accumulation of immature white blood cells. Based on revenue, Gleevec was one of Novartis’s top ten pharmaceutical products in 2017.

Novartis Oncology drug Kisqali (ribociclib) in Phase III MONALEESA (Mammary Oncology Assessment of LEE011’s (Ribociclib’s) Efficacy and Safety) trials, was reported in December 2018 to demonstrate efficacy and tolerability in combination with endocrine therapy in advanced breast cancer patients with visceral involvement. Kisqali (ribociclib) is a cyclin-dependent kinase inhibitor that inhibits cyclin-dependent kinase 4 and 6 (CDK4/6), proteins that when over active can promote cancer cell division and cancer growth. The drug is an orally available small molecule that acts by blocking phosphorylation of the retinoblastoma protein, which prevents cell-cycle progression. Kisqali is also in the NATALEE study, a Phase III clinical trial with endocrine therapy to treat early breast cancer.

Timeline

May 15, 2020

Novartis CEO says any new coronavirus vaccine will take two years.

October 1, 2019

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence.

April 1, 2019

Novartis agrees to pay $310 million, with the possibility for more later, for some assets of Boston-based IFM Therapeutics.

February 14, 2018

Novartis raises a $6,500,000 grant from Bill & Melinda Gates Foundation.

2010

Novartis bought Alcon's eye surgery and contact lens portfolio in stages through 2010 for $52 billion from Nestle.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Novartis Grant (money), February 2018
Grant (money)
6,500,000
February 14, 2018
Bill & Melinda Gates Foundation
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Barry X Lynn

Investor

Chris Ilsley

President, Chief Executive Officer

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Ken Londoner

Advisor

Mike Ryan

Investor

prakash thombre

Investor

Stacia Danielle Sullivan

Founder

Steven Zeppenfeld

Investor

V and K Law

Attorney

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Heather Landi
August 12, 2020
FierceHealthcare
There is a potential deal on the table for Proteus Digital Health to exit bankruptcy in a $15 million sale to Otsuka Pharmaceutical. In an 11th-hour play, a group of investors including drug giant Novartis are trying to push off that sale.
Amirah Al Idrus
July 17, 2020
FierceBiotech
Eli Lilly's anti-IL-23 antibody beat placebo at clearing psoriasis symptoms in a phase 3 study, teeing up regulatory filings across the globe. But that's not all--the drug also outshone Novartis' blockbuster Cosentyx in the same study.
Conor Hale
July 7, 2020
FierceBiotech
Novartis has teamed up with smart inhaler developer Propeller Health to package and ship its digital medication-tracking platform alongside the Big Pharma's newly approved asthma treatment in Europe.
Steven Levy
June 30, 2020
Wired
Vas Narasimhan talks about drug prices, vaccine development, the rise and fall of hydroxychloroquine, and how Big Pharma might win back the trust of consumers.
Nick Paul
June 15, 2020
FierceBiotech
UCB has presented detailed phase 3 data on psoriasis prospect bimekizumab, raising expectations that it can deliver a telling blow to Novartis' Cosentyx in an upcoming head-to-head study. Shares in UCB, a company valued above $20 billion, jumped 14% in response to the readout.
Alex Keown
June 11, 2020
BioSpace
In the latest legal action, the attorneys general from 46 states, the District of Columbia and four U.S. territories accused the drug makers of conspiring to rig the price of approximately 80 generic drugs between 2009 and 2016
Alex Keown
June 3, 2020
BioSpace
On Tuesday, the FDA extended its review of the Supplemental Biologics License Application for Arzerra in this indication by three months.
Gail Dutton
June 1, 2020
BioSpace
Cell and gene therapies must scale up on an industrial level if they are to deliver their full potential to patients worldwide, according to speakers at the International Society of Cell Therapy meeting, ISCT Paris 2020 Virtual, May 29.
May 29, 2020
BioSpace
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery - read this article along with other careers information, tips and advice on BioSpace
Reuters Editorial
May 28, 2020
IN
Novartis's gene therapy unit AveXis has signed a manufacturing deal to help produce a novel genetic COVID-19 vaccine candidate being developed by U.S. researchers in Massachusetts, a spokeswoman for the Swiss drugmaker confirmed on Thursday.
BioSpace
May 18, 2020
BioSpace
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced the appointment of Leopold Bertea, Ph.D., to the role of Senior Vice President of Technical Operations - Europe.
Reuters
May 15, 2020
@bsindia
A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts.
Reuters Editorial
May 15, 2020
IN
Any vaccine to fight the new coronavirus will not be ready for use for at least two years, the chief executive of Swiss pharmaceutical company Novartis, which no longer makes vaccines itself, told a German newspaper.
Amirah Al Idrus
May 8, 2020
FierceBiotech
Although gene therapy has opened a new realm of possibilities, its delivery vehicles have held it back. Dyno Therapeutics is on a mission to change that--and it's coming out of stealth with artificial-intelligence-powered technology and partnerships with Novartis and Sarepta Therapeutics that could net it up to $2 billion.
Madison Hogan
April 29, 2020
AmericanInno
Check out the most important mergers, acquisitions and investments from Atlanta technology companies from April 2020.
Reuters Editorial
April 29, 2020
U.S.
Novartis on Wednesday won a new European approval for its inflammation drug Cosentyx in a form of arthritis, as the Swiss drugmaker predicts broadening use of its top-selling medicine will eventually push annual sales beyond $5 billion.
Reuters Editorial
April 28, 2020
U.S.
Swiss drugmaker Novartis reported rising first-quarter sales and profit that beat analyst expectations and confirmed its 2020 targets as the coronavirus pandemic prompted patients to stock up on their prescriptions in advance.
Julien Ponthus
April 22, 2020
IN
Shielded by the resilience of three behemoth defensive stocks, the Swiss blue-chip index has comfortably weathered the coronavirus storm compared with other European benchmarks which have sustained up to three times more damage.
April 20, 2020
WebWire
, , , , • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease , , • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease , , • Company will also make its hydroxychloroquine intellec...
April 7, 2020
clinicaltrials.gov
Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness - Full Text View.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.